4BIO Ventures II | 4biocapital

HOME
ABOUT US
- SOCIAL IMPACT
STRATEGY
TEAM
PORTFOLIO
- VENTURE PORTFOLIO
- PAST PORTFOLIOS
4BATLE ICAV
NEWS ROOM
CONTACT
More

Use tab to navigate through the menu items.

NEWS ROOM

Apr 20

4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics

4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics

Apr 20

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

Oct 21, 2020

4BIO Capital leads SparingVision’s €44.5 million financing round

4BIO Capital leads SparingVision’s €44.5 million financing round

Jun 8, 2020

4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin

4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin

ARCHIVE

April 2021
March 2021
January 2021
December 2020
November 2020
October 2020
July 2020
June 2020
May 2020
March 2020
November 2019
September 2019
February 2019
November 2018
August 2018
May 2018
April 2018
March 2018
January 2018
December 2017

SEARCH BY TAGS

portfolio
Orchard Therapeutics
4BIO Ventures II
appointment
approval
investment
ADC Therapeutics
advisory board
Spark Therapeutics
AAV
acquisition
IPO
publication
review
SparingVision
Takeda
TiGenix
4BATLE
awards
BLA
clinical trials
CodeBio
EGLS
Kyowa Kirin
pricing
Redpin Therapeutics
results
venture

FOLLOW US

4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

4BIO Partners LLP is an SEC Registered Investment Advisor

© 2015-2021 by 4BIO Partners LLP